Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-10-11 M&A Activity
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : Sanofi en discussions pour céder une participation majoritaire dans Opella
M&A Activity Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces that Sanofi is in discussions regarding the potential sale of a majority stake in its consumer healthcare division, Opella. This is a significant corporate action announcement related to a potential transaction (divestiture/spin-off preparation). This type of announcement, which details strategic moves, negotiations, and potential structural changes, fits best under the category of M&A Activity (TAR) or potentially Capital/Financing Update (CAP) if it were purely about raising funds, but the focus here is on a major asset transaction. Given the context of 'discussions for potential sale' of a business unit, TAR (Merger & Acquisition Activity) is the most appropriate classification, as divestitures are often grouped with M&A activities. It is not a formal regulatory filing like 10-K, nor is it a short announcement of a report (RPA/RNS).
2024-10-11 French
Press Release: Sanofi in discussions to sell a controlling stake in Opella
M&A Activity Classification · 99% confidence The document is explicitly titled "Press Release" and announces that Sanofi is "in discussions to sell a controlling stake in Opella." This is a corporate action announcement regarding a potential divestiture or major transaction involving a business unit. This type of announcement, which details strategic moves, negotiations, and potential future transactions (like M&A or major asset sales), fits best under the category related to Mergers & Acquisitions or significant corporate transactions. Since there is no specific code for 'Strategic Negotiation Announcement,' the closest fit among the provided options is 'M&A Activity' (TAR), as the sale of a controlling stake is a form of divestiture/transaction. It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K. It is a high-level announcement, not a detailed report or a transcript.
2024-10-11 English
Communiqué de presse : De nouvelles données sur le Beyfortus présentées à l’IDWeek confirment son efficacité en situation réelle contre les infections dues au VRS et le risque d’hospitalisation chez l
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces new data regarding the drug Beyfortus to be presented at the IDWeek 2024 conference. It contains quotes from an executive, details about manufacturing updates, a schedule of presentations, and standard sections like 'About RSV', 'About Beyfortus', and 'About Sanofi', concluding with contact information and forward-looking statements. This format is characteristic of a corporate press release announcing scientific or business developments, rather than a formal regulatory filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). Since it is a general announcement about company news/data presentation, and it doesn't fit the specific categories like AGM-R, CT, or DIV, the most appropriate general category for a corporate announcement that isn't a specific financial report or management change is often the general Regulatory Filings/Announcements category, or if we consider the nature of the announcement (scientific data release), it is a general corporate communication. Given the options, and since it is not a formal financial report, a management change, or a specific regulatory filing like DIRS or DIV, it falls best under the general regulatory/corporate announcement category, which is RNS, as it is a public announcement of corporate activity/data presentation.
2024-10-09 French
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Regulatory Filings Classification · 99% confidence The document is explicitly titled "Press Release" and announces new data regarding the drug Beyfortus to be presented at the IDWeek 2024 annual meeting. It contains quotes from an Executive VP, details about manufacturing updates, and contact information for Media and Investor Relations. This format is characteristic of an initial announcement of company news, often related to clinical data or product updates, which aligns best with an Earnings Release (ER) if it were financial results, or more generally, a type of corporate announcement. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it is a formal announcement of company progress/data presentation, it functions similarly to an Earnings Release in terms of being a primary, timely corporate communication. However, given the focus is on scientific data presentation and manufacturing updates rather than quarterly financial performance highlights, it is a general corporate announcement. In the provided definitions, 'Earnings Release (ER)' is the closest fit for a primary, non-financial-specific announcement of significant company activity/data, though 'Regulatory Filings (RNS)' is a possible fallback. Given the structure and purpose (announcing data presentation and manufacturing progress), it is a high-level corporate communication. Since it is not a formal regulatory filing like a 10-K or a specific notice, and it's a press release detailing product/data updates, I will classify it as a general corporate announcement, which often falls under RNS if ER is strictly for financial results. However, many companies use ER templates for major product/data announcements. Given the context of financial reporting databases, this is a key corporate update. I will lean towards RNS as the most appropriate general announcement category when ER is reserved for financial results, as this is primarily a scientific/product update press release.
2024-10-09 English
6-K
Regulatory Filings
2024-10-02 English
Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces the FDA approval of Dupixent for COPD treatment. It details the clinical trial results (BOREAS and NOTUS), quotes executives from Sanofi and Regeneron, and provides background information on COPD and the drug development program. This format—a formal announcement of a significant event (drug approval) containing key data points and quotes, rather than a comprehensive regulatory filing (like 10-K or IR) or a transcript—is characteristic of an Earnings Release (ER) or a general press release announcing material news. Since the core content is the announcement of a major regulatory milestone and associated clinical data, and it is not a transcript (CT) or a formal quarterly/annual report (IR/10-K), the closest fit among the provided options for a major, non-financial results announcement is often categorized under general news releases. However, given the focus on clinical trial results and regulatory milestones, it functions as a major corporate announcement. In many databases, such detailed press releases announcing regulatory achievements or key trial data are often classified as Earnings Releases (ER) if they contain quantitative results, or sometimes as Regulatory Filings (RNS) if they are purely informational. Since this is a detailed announcement of a regulatory event and clinical efficacy, and it is not a transcript or a full financial report, it most closely aligns with the function of an Earnings Release (ER) which announces period results/milestones, or potentially a Regulatory Filing (RNS) as a fallback. Given the structure and the inclusion of specific efficacy data (reduction in exacerbations, VEMS improvements), it functions similarly to an announcement of positive results, making ER a strong candidate, though RNS is the general regulatory fallback. Since it is a press release announcing a major regulatory event and clinical data, and not a transcript or a full financial report, I will classify it as an Earnings Release (ER) as it communicates key performance/approval metrics, or RNS if it is purely regulatory news. Given the detailed clinical data presentation, ER is slightly more appropriate than the generic RNS, but RNS is the safest fallback for non-standard filings. I will select RNS as the most appropriate general regulatory announcement category when ER is reserved strictly for quarterly financial summaries, which this is not.
2024-09-27 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.